We are live on ! Find out more
HUMA icon

Humacyte

142 hedge funds and large institutions have $79.8M invested in Humacyte in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 46 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.84% less ownership

Funds ownership: 36.69% → 28.85% (-7.8%)

10% less funds holding

Funds holding: 157 → 142 (-15)

15% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 46

22% less call options, than puts

Call options by funds: $1M | Put options by funds: $1.28M

45% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 29

79% less capital inflows, than outflows

Capital inflows: $5.96M | Capital outflows: $28M

Holders
142
Holders Change
-15
Holders Change %
-9.55%
% of All Funds
1.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
39
Reduced
46
Closed
29
Calls
$1​M
Puts
$1.28​M
Net Calls
-⁠$284​K
Net Calls Change
-⁠$19​K

HUMA Hedge Fund Activity: Q3 2025 in Review

142 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q3 2025, worth a combined $79.8M — down 33% from $119M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of HUMA and 16 opened new positions — a net loss of 13 holders — while 46 trimmed existing stakes and 39 added.

The largest buyer was Morgan Stanley, adding an estimated $1.41M. The largest seller was CenterBook Partners, cutting an estimated $6.16M.

  • 142 institutional investors held Humacyte (HUMA) as of Q3 2025, down from 157 in Q2 2025.
  • Funds reported $79.8M of Humacyte stock for Q3 2025, down 33% quarter-over-quarter.
  • 16 funds opened new Humacyte positions in Q3 2025 and 29 closed out, a net change of -13 holders.
  • The largest Humacyte buyer in Q3 2025 was Morgan Stanley, an estimated $1.41M added.
  • The largest Humacyte seller in Q3 2025 was CenterBook Partners, an estimated $6.16M sold.

Based on aggregated 13F filings for Q3 2025.